Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial

Editor By No Comments1 Min Read

Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents “Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial” at the 14th International Kidney Cancer Symposium.

Share.

Related Posts